F2 and diphtheria: In the United Kingdom, vaccines for the national program are centrally procured and distributed and in July 2014, the vaccine product being offered to pregnant women changed from dT5aP-IPV (pertussis toxin [PT]: 2.5 μg; filamentous hemagglutinin [FHA]: 5 μg; pertactin [PRN]: 3 μg; fimbriae types 2 and 3 [FIM]: 5 μg) to diphtheria–tetanus–3-component acellular pertussis (dT3aP-IPV) (PT: 8 μg; FHA: 8 μg; PRN: 2.5 μg).